Alligator Bioscience AB (publ)
STO: ATORX.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Søren Bregenholt
- Employees
- 33
- Headquarters
- Lund, Sweden
- IPO year
- 2016
- Market cap
- SEK 8.0M
- Website
- https://www.alligatorbioscience.se
Loading ATORX…
Loading profile data…Frequently asked questions about ATORX
What does Alligator Bioscience AB (publ) (ATORX.ST) do?
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molec...
Where does ATORX.ST trade?
Alligator Bioscience AB (publ) (ATORX.ST) trades on the Stockholm Stock Exchange.
What sector is ATORX.ST in?
Alligator Bioscience AB (publ) (ATORX.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Alligator Bioscience AB (publ)?
Søren Bregenholt is the chief executive officer of Alligator Bioscience AB (publ) (ATORX.ST).
Where is Alligator Bioscience AB (publ) headquartered?
Alligator Bioscience AB (publ) is headquartered in Sweden.
Does ATORX.ST pay a dividend?
Alligator Bioscience AB (publ) (ATORX.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ATORX.ST go public?
Alligator Bioscience AB (publ) (ATORX.ST) completed its initial public offering in 2016.